Robin Joyce MD M.Div, MSc

Hematologic Oncology

Director of Clinical Lymphoma Program

330 Brookline AveBeth Israel Medical CenterBoston, MA 02215
Phone+1 617-667-9920
Fax+1 617-667-9922

Dr. Joyce is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Joyce's full profile Already have an account?

Summary

Dr. Robin Joyce is an oncologist in Boston, MA and is affiliated with Beth Israel Deaconess Medical Center. She received her medical degree from University of Massachusetts Medical School and has been in practice 25 years. She specializes in hematologic malignancy. She is the director of the clinical lymphoma program. She has expertise in non Hodgkin lymph’s and Hodgkin lymphoma. She also uses cell therapy and transplantation.

Education & Training

Harvard Medical SchoolM.Msc, Clinical Investigation, 1997 - 1998
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1994 - 1997
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Internal Medicine, 1991 - 1994
University of Massachusetts Medical SchoolClass of 1991
Andover Newton Theological SchoolM.Div, Theology, 1981 - 1984

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MA State Medical License 1995 - 2027
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification Online Medical Record, Beth Israel Deaconess Medical Center, 2012-2017
CMS Meaningful Use Stage 2 Certification Quality Data Center, Massachusetts eHealth Collaborative (MAeHC), 2012-2017
CMS Meaningful Use Stage 1 Certification Online Medical Record, Beth Israel Deaconess Medical Center, 2012-2017

Clinical Trials

Bortezomib Plus Rituximab for EBV+ PTLD Start of enrollment: 2011 Nov 01
Completed
Phase 2
Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Start of enrollment: 2010 Mar 01
Completed
Phase 1, Phase 2
Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML) Start of enrollment: 2011 Sep 01
Terminated
Phase 1

Publications & Presentations

PubMed

1 citations
High CD34-positive cell dose in matched unrelated donor allogeneic hematopoietic stem cell transplant is not associated with graft-versus-host disease or mortality.
Zachary M Avigan, Ajoy L Dias, Laura E Dodge, Jon E Arnason, Robin M Joyce
Transfusion. 2024-06-01
3 citations
Comparison of whole-genome and immunoglobulin-based circulating tumor DNA assays in diffuse large B-cell lymphoma.
Reid W Merryman, Justin Rhoades, Kan Xiong, Robert A Redd, Katherine Antel
Hemasphere. 2024-04-01
18 citations
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.
Reid W Merryman, Robert A Redd, Eleanor Taranto, Gulrayz Ahmed, Erin Jeter
Blood Advances. 2023-09-12

Abstracts/Posters

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
Robin M. Joyce, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
Robin M. Joyce, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...
Robin M. Joyce, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018